Liminatus Pharma, Inc.
NGM: LIMNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Liminatus Pharma, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LIMN Z-Score →About Liminatus Pharma, Inc.
Healthcare
Biotechnology
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
📊 Fundamental Analysis
Liminatus Pharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $0.19, LIMN currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $0.16 - $33.66).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$8.41M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.63
52W High
$33.66
52W Low
$0.16
Avg Volume
9.19M
Day High
Day Low